The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...

In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Shortages of tirzepatide, sold as a diabetes drug (Mounjaro) and a weight-loss medication (Zepbound), have fueled demand for compounding pharmacies to make their own versions of the medicine, which ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

(The Hill) – Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that ...